FABP4 and adenocarcinoma: In contrast, no statistical differences in the incidence rate of prostatic burdens (e.g., hyperplasia, PIN, primary adenocarcinoma, and metastasis) were observed between FABP4−/− TRAMP mice consuming HF or CD (Figure 2A,B).